DAWN
NASDAQ
US
Day One Biopharmaceuticals, Inc. - Common Stock
$21.45
▲ +$0.03
(+0.14%)
Vol 1.4M
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$956.9M
ROE
-32.1%
Margin
-113.5%
D/E
0.00
Beta
-1.30
52W
$6–$14
Wall Street Consensus
13 analysts · Apr 20260
Strong Buy
0
Buy
10
Hold
1
Sell
2
Strong Sell
0.0%
Buy Rating
Price Chart
Similar Stocks
BCRX
BioCryst Pharmaceuticals Inc
$1.6B
GRAL
Grail Inc
$3.3B
RLAY
Relay Therapeutics Inc
$1.5B
MLYS
Mineralys Therapeutics Inc
$2.9B
SNDX
Syndax Pharmaceuticals Inc
$1.8B
ADMA
ADMA Biologics Inc
P/E 20.7
$4.3B
RARE
Ultragenyx Pharmaceutical Inc
$2.2B
TYRA
Tyra Biosciences Inc
$1.4B
CLDX
Celldex Therapeutics Inc
$1.8B
AGIO
Agios Pharmaceuticals Inc
$1.6B
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.15 | $-0.21 | $-0.06 |
| Sep 2025 | $-0.30 | $-0.19 | +$0.11 |
| Jun 2025 | $-0.36 | $-0.29 | +$0.07 |
| Mar 2025 | $-0.45 | $-0.35 | +$0.10 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $29.2M | $30.8M | $33.9M | $39.8M | $53.7M |
| Net Income | — | -$65.7M | -$36.0M | -$30.3M | -$19.7M | -$21.3M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -19.0% | -19.0% | -19.0% | -19.0% | -32.0% | -32.0% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -89.4% | -50.6% | -50.6% | -50.6% | -113.5% | -113.5% |
| Gross Margin | 88.9% | 94.0% | 94.0% | 94.0% | 89.4% | 89.4% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 9.65 | 9.65 | 9.65 | 9.65 | 8.68 | 8.68 |
Key Ratios
ROA (TTM)
-28.2%
P/S (TTM)
7.16
P/B
2.5
EPS (TTM)
$-1.48
CF/Share
$-2.29
52W High
$13.53
52W Low
$5.64
$5.64
52-Week Range
$13.53
Financial Health
Free Cash Flow
-$14.1M
Net Debt
-$194.3M
Cash
$197.1M
Total Debt
$2.8M
As of Dec 31, 2025
How does DAWN compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
DAWN valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
7.2
▼
44%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
2.5
▲
3%
above
peers
(2.5)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
DAWN profitability vs Biotechnology peers
ROE
-32.1%
▲
52%
above
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
-113.5%
▲
60%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
89.4%
▲
14%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-28.2%
▲
40%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
DAWN financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
8.7
▲
95%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
-1.3
▼
234%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
DAWN fundamentals radar
DAWN
Peer median
Industry
DAWN profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
DAWN vs peers: key metrics
Latest News
No related news yet